Novel Oral Drug TLC-2716 Reduces Triglycerides by 38% and Remnant Cholesterol by 61% in Phase 1 Trial
核心洞察
TLC-2716, an oral liver X receptor (搜索) inverse agonist, demonstrated significant lipid-lowering effects in a 14-day Phase 1 trial involving 100 healthy adults.
The drug reduced triglycerides by up to 38.5% and postprandial remnant cholesterol by up to 61% at the highest doses tested.
TLC-2716 specifically targets liver and gut LXR activity while avoiding systemic effects, addressing a long-standing challenge in lipid metabolism drug development.
A novel oral compound designed to target lipid metabolism specifically in the liver and gut has shown promising results in its first human trial, offering potential new treatment options for patients with elevated triglycerides and cardiovascular risk. The drug, TLC-2716, reduced blood triglycerides by up to 38.5% and remnant cholesterol by as much as 61% in a Phase 1 study published in Nature Medicine.
The randomized, placebo-controlled trial involved 100 healthy adults who received either TLC-2716 or placebo for 14 days. Led by Johan Auwerx at the Swiss Federal Institute of Technology in Lausanne (EPFL) and Mani Subramanian at OrsoBio (搜索), the study represents the first human testing of this targeted approach to lipid management.
Addressing a Long-Standing Challenge
The development of TLC-2716 addresses what researchers describe as a dilemma that has "held back the field for years" - how to reduce blood fat levels without affecting the beneficial functions of liver X receptors (LXR) elsewhere in the body. LXRα (搜索) controls genes involved in making and handling fats in the liver, gut, and fatty tissue, and plays a role in protective cholesterol pathways.
"We confirmed that higher NR1H3 (搜索) [the gene that produces LXRα (搜索)] expression in blood causes an increase in TG [triglycerides] in humans, and its expression is also associated with HDL-C [aka 'good' cholesterol] and liver disease markers," the study authors write.
The research team initially identified the target through analysis of large human genetics databases, using Mendelian randomization to establish causal links between LXRα (搜索) expression and metabolic disorders. This genetic evidence pointed to LXRα variants highly expressed in the liver as key drivers of elevated triglycerides.
Mechanism and Preclinical Development
TLC-2716 functions as an "inverse agonist" for LXRα (搜索), meaning it makes the receptor signal the opposite effect to what it would normally do, rather than simply blocking its activity. Crucially, the compound was designed to act primarily in the liver and gut while limiting exposure to other tissues where inhibiting LXR could be harmful.
Preclinical testing in rodent models of metabolic disease, human diseased liver organoids, and non-human primates demonstrated the compound's effectiveness in lowering blood fats. Toxicology studies confirmed that TLC-2716 largely stays in the liver and gut, addressing safety concerns about systemic LXR inhibition.
Clinical Trial Results
In the Phase 1 trial, participants were enrolled across single-ascending dose and multiple-ascending dose cohorts. The multiple-dose portion tested TLC-2716 at doses of 0.5 mg, 2 mg, 6 mg, or 12 mg once daily for 14 days, compared to placebo.
The strongest lipid effects occurred at the 6 mg and 12 mg doses. High doses reduced blood triglycerides by up to 38.5%, while postprandial remnant cholesterol dropped by as much as 61% after a meal. The study also reported improvements in other clinically relevant lipid markers, including non-high-density lipoprotein cholesterol and LDL particle number.
Participants started with relatively normal lipid levels and were not taking other lipid-lowering drugs, suggesting the drug's effects could be even more pronounced in patients with elevated baseline lipid levels.
Safety Profile
"All doses of TLC-2716 were safe and well tolerated," the researchers report. The trial met its primary safety and tolerability endpoints, with no serious adverse events, treatment discontinuations, or clinically concerning changes in safety laboratory results, electrocardiogram findings, or vital signs during the 14-day study period.
Reported side effects were mostly mild and included headache and gastrointestinal symptoms. The drug produced "substantial improvements in plasma lipid metabolism," and its oral administration offers advantages in terms of "patient convenience, reduced cost and the potential to combine with other lipid-lowering therapies."
Clinical Significance
Triglycerides and remnant cholesterol are increasingly recognized as clinically relevant risk markers, particularly in patients with residual cardiovascular risk despite standard lipid-lowering therapy. Metabolic disorders occur when fat production from digestion outpaces the body's ability to use it, leading to excess fat accumulation on arterial walls and plaque formation.
This process contributes to atherosclerotic cardiovascular diseases (搜索), including coronary heart disease (搜索), as well as acute pancreatitis (搜索) and metabolic dysfunction-associated steatotic liver disease (搜索) (MASLD (搜索)), previously known as non-alcoholic fatty liver disease.
Next Steps
While the results are promising, TLC-2716 remains in the earliest phases of clinical testing. The next step involves longer trials in overweight and obese individuals with poor lipid profiles, specifically those with hypertriglyceridemia (搜索) and MASLD (搜索).
The researchers note that their preliminary findings from healthy volunteers "must be interpreted cautiously," but the "consistent metabolic benefits" seen across the Phase 1 trial and animal studies support further clinical testing to determine whether TLC-2716 could help treat cardiometabolic diseases.
The compound's ability to selectively reduce LXR activity in the liver and gut may offer a new complementary approach to tackle high triglycerides and related metabolic disorders, potentially filling an important gap in current lipid management strategies.